Literature DB >> 3516681

Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents.

F Meunier.   

Abstract

The serum levels of two imidazoles, ketoconazole and Bayer n7133, when administered alone or in combination with rifampin, were measured in volunteers and the serum antifungal activity was determined against various fungal strains. Serum levels were measured by high pressure liquid chromatography and correlated with serum fungistatic activity as determined in microtiter plates. Ketoconazole showed a wide range of serum levels, suggesting individual variations. The addition of two doses of rifampin significantly decreased serum levels of both imidazoles and no synergism was observed. Serum fungicidal activity could only occasionally be demonstrated against one strain of Candida albicans and Candida stellatoidea. Serum fungistatic activity significantly correlated with the serum levels of both imidazoles. This approach should be investigated in patients to establish its potential clinical relevance for managing invasive fungal infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516681     DOI: 10.1007/bf02013478

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  21 in total

1.  The influence of gastric acidity on the bio-availability of ketoconazole.

Authors:  J W Van Der Meer; J J Keuning; H W Scheijgrond; J Heykants; J Van Cutsem; J Brugmans
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

2.  Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

Authors:  I M Hann; H G Prentice; R Corringham; H A Blacklock; M Keaney; M Shannon; P Noone; E Gascoigne; J Fox; E Boesen; M Szawatkowski; A V Hoffbrand
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

3.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

4.  Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

Authors:  E Drouhet; B Dupont
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

5.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

Authors:  G Medoff; G S Kobayashi; C N Kwan; D Schlessinger; P Venkov
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

6.  The influence of rifampin on quinidine and digoxin.

Authors:  H I Bussey; G J Merritt; E G Hill
Journal:  Arch Intern Med       Date:  1984-05

7.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Impairing effect of food on ketoconazole absorption.

Authors:  P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu; P Ottoila
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

9.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

10.  Ketoconazole for treatment of disseminated coccidioidomycosis.

Authors:  A Catanzaro; H Einstein; B Levine; J B Ross; R Schillaci; J Fierer; P J Friedman
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

View more
  5 in total

Review 1.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Sensitivity testing with ketoconazole in an assay containing Candida albicans, human polymorphonuclear leukocytes and serum.

Authors:  T M Bauer; W Kronsteiner; M Bassler; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

Review 3.  Candidiasis.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

4.  Successful treatment with liposomal amphotericin B in two patients with persisting fungemia.

Authors:  J P Sculier; D Bron; A Coune; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

5.  Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate.

Authors:  N Collette; P van der Auwera; A P Lopez; C Heymans; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.